Fospropofol is a sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. Fospropofol is a water soluble prodrug and is converted to propofol in the liver.
- Mechanism
- Curator reviewed
After in-vivo conversion of fospropofol into propofol by endothelial alkaline phosphatase, propofol crosses the blood-brain barrier, binds to GABA-A receptors and acts as an agonist. By binding to GABA-A receptor, it will cause an increase in chloride conductance, thus inhibiting the firing of new action potentials in the post-synaptic neuron.
- Primary indication
- For monitored anaesthesia care sedation in patients undergoing diagnostic procedures like bronchoscopy and colonscopy or minor surgical procedures like arthroscopy and bunionectomy.Curator reviewed · 1 structured indication
- Formula / weight
- C13H21O5P · 288.2766 g/mol (avg)
- First approval
- United States, 2008
- Code names
- DEA No. 2138 · GPI 15715
Resolves to
QVNNONOFASOXQV-UHFFFAOYSA-NSMILESCC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Fospropofol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account